scholarly journals Clinicopathological significance of matrix metalloproteinase-7 protein expression in esophageal cancer: a meta-analysis

2015 ◽  
pp. 3729 ◽  
Author(s):  
Bin Yang ◽  
Shuai Miao ◽  
Shi-Yao Zhou ◽  
Chun-Shan Han ◽  
Le-Ning Zhang ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Matrix Metalloproteinase ◽  
Protein Expression ◽  
Meta Analysis ◽  
Matrix Metalloproteinase 7 ◽  
Clinicopathological Significance

Clinicopathological significance of Bmi-1 overexpression in esophageal cancer: a meta-analysis

2018 ◽  
Vol 12 (1) ◽  
pp. 71-81 ◽  
Author(s):  
Jihong Liu ◽  
Kai Liu ◽  
Xianli Jiang ◽  
Xueli Wang ◽  
Yunzhao Chen ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Meta Analysis ◽  
Clinicopathological Significance

scholarly journals A systematic review of blood biomarkers with individual participant data meta-analysis of matrix-metalloproteinase-7 in IPF

2021 ◽  
pp. 2101612
Author(s):  
Fasihul A. Khan ◽  
Iain Stewart ◽  
Gauri Saini ◽  
Karen A. Robinson ◽  
R. Gisli Jenkins
Keyword(s):  
Systematic Review ◽  
Matrix Metalloproteinase ◽  
Disease Progression ◽  
Meta Analysis ◽  
Secondary Outcome ◽  
Individual Participant Data ◽  
Increased Risk ◽  
Matrix Metalloproteinase 7 ◽  
Individual Participant ◽  
Poor Outcomes

BackgroundBlood derived biomarkers have been extensively described as potential prognostic markers in idiopathic pulmonary fibrosis (IPF), but studies have been limited by analyses using data-dependent thresholds, inconsistent adjustment for confounders and an array of endpoints, thus often yielding ungeneralisable results. Meta-analysis of individual participant data (IPD) is a powerful tool to overcome these limitations. Through systematic review of blood derived biomarkers, sufficient studies with measurements of Matrix Metalloproteinase-7 (MMP-7) were identified to facilitate standardised analyses of the prognostic potential of this biomarker in IPF.MethodsElectronic databases were searched on 12th November 2020 to identify prospective studies reporting outcomes in patients with untreated IPF, stratified according to at least one pre-specified biomarker, measured at either baseline, or change over three months. Individual participant data (IPD) was sought for studies investigating MMP-7 as a prognostic factor. The primary outcome was overall mortality according to standardised MMP-7 z-scores, with a secondary outcome of disease progression in 12 months, all adjusted for age, gender, smoking and baseline FVC.ResultsIPD was available for nine studies out of twelve identified, reporting outcomes from 1664 participants. Baseline MMP-7 levels were associated with increased mortality risk (adjusted HR1.23, 95%CI 1.03;1.48, I2=64.3%) and disease progression (adjusted OR1.27, 95%CI 1.11;1.46, I2=5.9%). In limited studies, three-month change in MMP-7 was not associated with outcomes.ConclusionIPD meta-analysis demonstrated greater baseline MMP-7 levels were independently associated with an increased risk of poor outcomes in patients with untreated IPF, whilst short term changes did not reflect disease progression.

scholarly journals Prognostic Significance of Matrix Metalloproteinase-7 in Gastric Cancer Survival: A Meta-Analysis

PLoS ONE ◽  
2015 ◽  
Vol 10 (4) ◽  
pp. e0122316 ◽  
Author(s):  
Saeed Soleyman-Jahi ◽  
Saharnaz Nedjat ◽  
Afshin Abdirad ◽  
Niloofar Hoorshad ◽  
Reza Heidari ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Matrix Metalloproteinase ◽  
Cancer Survival ◽  
Meta Analysis ◽  
Prognostic Significance ◽  
Matrix Metalloproteinase 7

scholarly journals Qigesan reduces the motility of esophageal cancer cells via inhibiting Gas6/Axl and NF-κB expression

2019 ◽  
Vol 39 (6) ◽  
Author(s):  
Lingyu Kong ◽  
Zhongbing Wu ◽  
Yang Zhao ◽  
Xin Lu ◽  
Huijuan Shi ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Matrix Metalloproteinase ◽  
Protein Expression ◽  
Cell Lines ◽  
Cultured Cells ◽  
Matrix Metalloproteinase 2 ◽  
Dependent Manner ◽  
Concentration Dependent Manner ◽  
Protein Activation ◽  
Downstream Signaling

AbstractThe present study is mainly to explore the mechanism that how Qigesan (QGS) affects the movement capacity of esophageal cancer (EC) cell. QGS incubates ECA109 and TE1 cell lines and detecting the motility of tumor cells by different experiments. Growth arrest-specific 6 (Gas6) and Anexelekto (Axl) were co-localized, and then detecting Gas6, Axl signaling pathway, and protein expression after QGS intervention. Similarly, Observing the signal localization and protein expression of P-phosphoinositide3-kinases (PI3K), P-AKT protein kinase B (AKT), P-nuclear factor-kappa B (NF-κB), matrix metalloproteinase-2 (MMP2), and matrix metalloproteinase-9 (MMP9). The results showed that the concentration of QGS was less than 200 ug/ml, and the cultured cells did not exceed 24 h, that no obvious cytotoxicity was observed. QGS significantly inhibited the mobility of ECA109 and TE1 cell lines in the concentration-dependent manner. In addition, QGS can regulate the Gas6/Axl pathway, inhibit the formation and localization of the Gas6/Axl complex, and reduce the protein activation of PI3K/AKT, NF-κB, MMP2, and MMP9. Experimental innovation shows that QGS can significantly slow down the mobility of EC cells by regulating the Gas6/Axl complex and downstream signaling pathways, and provides a theoretical basis for the pharmacological effects of QGS in the therapy of EC.

Sign in / Sign up

Export Citation Format

Share Document